U.S. Exceptionalism Continues Through 2025
As “the year of testing resiliency” comes to a close, many may wonder what to expect in 2025. Macro Analyst Richard de Chazal explores consumer spending, inflation, the strength of the U.S. dollar, and more, in his latest Economics Outlook.
Read more
William Blair Investment Management Named a 2024 Best Place to Work
For the 12th year, William Blair Investment Management was named a Best Place to Work in Money Management by Pensions & Investments magazine.
Read more
Monthly Macro: Tariffs Primer
William Blair macro analyst Richard de Chazal and consumer analyst Dylan Carden delve into the implications of the recent U.S. election results on tariffs, the specialty retail sector, and broader economic trends.
Listen to the podcast
William Blair Thinking
-
-
-
What Can Blue Whales, Shrews, and Megacities Tell Us About Energy Systems
In this episode of Plugged In, host Jed Dorsheimer engages with renowned theoretical physicist and author Geoffrey West, Ph.D., to explore the connections between biological scaling laws and economic systems, discussing how energy and network theories can provide insights into the growth and sustainability of cities and economies.
Our Mission, Vision, and Values
At William Blair, we're committed to our colleagues, our clients, and our communities. Serving our clients starts with the capabilities and collaboration of our team—making our employees our most important asset. When we create an environment where employees perform their best, our delivery for clients will be the best it can be.
Learn more about our mission, vision, and values
Global Community Partners
We are proud of our signature Global Community Partners program, through which employees nominate organizations to receive catalytic financial support and significant volunteerism opportunities every two years.
More about our community partnersOur Latest News
-
Elevation Oncology, Inc.: Initiation of Research Coverage
William Blair initiated research coverage of Elevation Oncology, Inc. (ELEV $0.56), a clinical-stage biotechnology company advancing a Phase I antibody-drug conjugate (ADC) against claudin 18.2, initially targeting gastric cancer/gastroesophageal junction (GEJ) adenocarcinoma with pancreatic cancer as an expansion opportunity.
-
Denali Therapeutics Inc.: Initiation of Research Coverage
William Blair initiated research coverage of Denali Therapeutics Inc. (DNLI $20.38), a clinical-stage biotechnology company developing treatments for CNS and other indications by leveraging its unique blood–brain barrier penetrating technology platform.
-
Join Our Team
Finding, attracting, and developing talented people is the foundation of our success. Learn about the promising career opportunities currently available at William Blair.
Search our job openings
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights